

Title (en)  
METHOD, COMPOSITIONS AND DEVICES FOR ADMINISTRATION OF NAKED POLYNUCLEOTIDES WHICH ENCODE BIOLOGICALLY ACTIVE PEPTIDES

Title (de)  
METHODE, ZUSAMMENSETZUNGEN UND VORRICHTUNGEN ZUR VERABREICHUNG VON NACKTEN POLYNUKLEOTIDEN, WELCHE FÜR BIOLOGISCH AKTIVE PEPTIDE KODIEREN

Title (fr)  
PROCEDE, COMPOSITIONS ET DISPOSITIFS POUR L'ADMINISTRATION DE POLYNUCLEOTIDES NUS QUI CODENT POUR DES PEPTIDES BIOLOGIQUEMENT ACTIFS

Publication  
**EP 0714308 A1 19960605 (EN)**

Application  
**EP 94926603 A 19940825**

Priority

- US 11244093 A 19930826
- US 9409661 W 19940825

Abstract (en)  
[origin: WO9505853A1] The invention encompasses methods of introducing biologically active peptides into a host (particularly for vaccination or transitory expression of a therapeutic peptide) by administration of polynucleotides which operatively encode for the peptide. In most embodiments, the polynucleotides are naked in the sense that they are neither complexed to colloidal preparations such as liposomes or associated with a genomic integrating vector. In one embodiment, the naked polynucleotides are administered to host tissues which have a high concentration of antigen presenting cells in them relative to other host tissues. It is believed that the polynucleotides are taken up and expressed locally, systemically and/or at locations remote from their point of entry in the host. In another embodiment, the polynucleotides express peptides which are effective in retarding, treating and preventing age-associated illnesses and loss of disease resistance in mammals. In this embodiment, subtherapeutic levels of the peptides are expressed at appropriate stages of the host's development. Devices and compositions for use in the methods of the invention are also described.

IPC 1-7  
**A61K 48/00**; C07H 19/00; C07H 21/00; A61B 17/20

IPC 8 full level  
**C07K 14/54** (2006.01); **C12N 15/09** (2006.01); **A61B 17/20** (2006.01); **A61K 9/00** (2006.01); **A61K 9/08** (2006.01); **A61K 9/12** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7088** (2006.01); **A61K 38/00** (2006.01); **A61K 38/22** (2006.01); **A61K 39/00** (2006.01); **A61K 39/35** (2006.01); **A61K 48/00** (2006.01); **A61N 1/30** (2006.01); **A61P 37/04** (2006.01); **A61P 43/00** (2006.01); **C07K 14/11** (2006.01); **C07K 14/495** (2006.01); **C07K 14/55** (2006.01); **C07K 14/77** (2006.01); **C07K 16/00** (2006.01); **C12N 5/10** (2006.01); **C12N 15/12** (2006.01); **C12N 15/87** (2006.01); **G01N 33/50** (2006.01); **G01N 33/569** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP US)  
**A61B 17/20** (2013.01 - EP); **A61B 17/205** (2013.01 - EP); **A61K 31/711** (2013.01 - EP); **A61K 39/00** (2013.01 - EP); **A61K 39/0005** (2013.01 - EP); **A61K 39/0011** (2013.01 - EP US); **A61K 39/35** (2013.01 - EP); **A61K 48/00** (2013.01 - EP); **A61P 37/04** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 14/005** (2013.01 - EP); **C07K 14/495** (2013.01 - EP); **C07K 14/5406** (2013.01 - EP); **C07K 14/55** (2013.01 - EP); **C07K 14/77** (2013.01 - EP); **C07K 16/00** (2013.01 - EP); **C12N 15/87** (2013.01 - EP); **G01N 33/5091** (2013.01 - EP); **G01N 33/56977** (2013.01 - EP); **G01N 33/6863** (2013.01 - EP); **G01N 33/6872** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **A61K 2039/51** (2013.01 - EP); **A61K 2039/5154** (2013.01 - EP); **A61K 2039/53** (2013.01 - EP); **A61K 2039/541** (2013.01 - EP); **C07K 2317/77** (2013.01 - EP); **C12N 2760/16022** (2013.01 - EP)

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9505853 A1 19950302**; AU 705889 B2 19990603; AU 7639194 A 19950321; CA 2169635 A1 19950302; CA 2169635 C 20021112; EP 0714308 A1 19960605; EP 0714308 A4 19980729; JP 2004331668 A 20041125; JP H09501936 A 19970225; MX 9406552 A 19970228

DOCDB simple family (application)  
**US 9409661 W 19940825**; AU 7639194 A 19940825; CA 2169635 A 19940825; EP 94926603 A 19940825; JP 2004168972 A 20040607; JP 50776695 A 19940825; MX 9406552 A 19940826